內科專科護理師指引

 【Sepsis Management - SSC 2021 Guidelines】

1. Implementation of Hour-1 Bundle: Initial lactate level measurement, obtaining blood cultures prior to administration of broad-spectrum antibiotics.

2. Fluid Resuscitation: For patients with sepsis-induced hypoperfusion or lactate ≥4 mmol/L, administer at least 30 mL/kg of IV crystalloid fluid within the first 3 hours.

3. Vasopressors: If MAP remains <65 mmHg despite fluid resuscitation, initiate norepinephrine as the first-line vasopressor.

4. Continuous Monitoring: Re-assess fluid status and tissue perfusion (MAP, Urine Output, Lactate clearance).

【AECOPD Management - GOLD 2024 Guidelines】

1. Oxygen Therapy: Target SpO2 maintained at 88-92% to prevent hypercapnic respiratory failure.

2. Pharmacological Intervention: Short-acting inhaled beta2-agonists (SABA) with/without anticholinergics (SAMA). 

3. Systemic Therapy: Consider systemic corticosteroids (e.g., Prednisolone 40mg QD for 5 days) and antibiotics if increased sputum purulence/volume.

4. Respiratory Support: Early initiation of Non-invasive Ventilation (NIV/BiPAP) if respiratory acidosis (pH < 7.35 or PaCO2 > 45 mmHg).

【Heart Failure Management - 2022 AHA/ACC/HFSA Guidelines】

1. GDMT Optimization: Implementation of four pillar therapies for HFrEF patients:

   - ARNI (Sacubitril/Valsartan) or ACEI/ARB

   - Evidence-based Beta-blockers (Carvedilol, Bisoprolol, or Metoprolol succinate)

   - Mineralocorticoid Receptor Antagonists (MRA)

   - SGLT2 Inhibitors (Dapagliflozin or Empagliflozin)

2. Monitoring: Evaluate renal function (BUN/Cr), electrolytes (K+), and blood pressure titration during the stabilization phase.

【Diabetes Care - ADA 2024 Standards of Care】

1. Organ Protection Strategy: For patients with established ASCVD, Heart Failure, or CKD, prioritize SGLT2 inhibitors or GLP-1 receptor agonists with proven cardiovascular/renal benefit.

2. Glycemic Targets: Individualized A1c goals (usually <7% for most non-pregnant adults) balanced with hypoglycemia risk assessment.

3. Screening: Annual monitoring of UACR (Urine Albumin-to-Creatinine Ratio) and eGFR for early detection of diabetic kidney disaese.

【NP Clinical Decision Framework】

1. Initial Assessment: Focused physical examination and review of vital signs (Identify Red Flags).

2. Diagnostic Logic: Review lab results (ABG, CXR, ECG) based on evidence-based guidelines (e.g., GOLD, SSC, AHA).

3. Collaborative Decision: Propose a pre-settled order or medical plan (Pharmacological + Non-pharmacological).

4. Monitoring & Follow-up: Evaluate patient response and adjust the management plan to optimize outcomes and reduce ALOS (Average Length of Stay).